Swiss Venture Capital Report 2017 (Swiss Venture Capital Report (startupticker))

Summary

• In 2016, 151 financing rounds of Swiss start-ups were reported, representing an increase of 26% compared with 2015.p.5
• Total invested capital in Swiss start-ups reached CHF 908.7 million in 2016, up from CHF 676 million in 2015.p.5
• The median value of all financing rounds in Switzerland remained constant at CHF 2.5 million.p.5
• Invested capital in the ICT sector grew by 110% or CHF 142 million to reach CHF 271 million in 2016.p.5
• Fintech start-ups attracted almost CHF 50 million in venture capital investment in 2016.p.5
• Biotech start-ups secured nearly CHF 400 million across 25 financing rounds in 2016.p.5
• Start-ups based in canton Vaud attracted more than CHF 460 million, accounting for more than half of the total Swiss venture investment.p.5

Key insights

1. The Top 20 venture capital rounds in 2016 totaled CHF 706 million, accounting for 78% of total capital invested.p.9
2. ADC Therapeutics completed the largest financing round of 2016 with CHF 104 million raised.p.9
3. More than 70% of growth financing capital invested in Swiss start-ups in 2016 came from foreign investors.p.7
4. Life sciences and healthcare IT represented 64% of total transaction volume in 2016 with CHF 577 million raised.p.18
5. Seed rounds more than doubled in number in 2016, growing to 43 completed transactions.p.20
6. Canton Vaud achieved the highest investment across biotech, medtech, ICT, and healthcare IT sectors in 2016.p.22
7. The year 2016 recorded five IPOs and two reverse takeovers involving venture-backed Swiss companies.p.26
8. EngMab was acquired by US multinational Celgene for a total purchase price of $600 million.p.29